Aquestive Therapeutics (NASDAQ:AQST) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

Several other research firms also recently commented on AQST. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Thursday, October 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.75.

Aquestive Therapeutics Stock Performance

Shares of AQST stock opened at $3.54 on Friday. Aquestive Therapeutics has a fifty-two week low of $2.93 and a fifty-two week high of $6.74. The stock’s 50-day simple moving average is $4.50 and its 200-day simple moving average is $4.21.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $7.56 million for the quarter, compared to analysts’ expectations of $11.02 million. Equities analysts anticipate that Aquestive Therapeutics will post -0.51 earnings per share for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In related news, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the sale, the insider owned 235,689 shares in the company, valued at $1,230,296.58. This represents a 3.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the completion of the sale, the chief executive officer owned 627,317 shares in the company, valued at approximately $2,647,277.74. This represents a 3.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,750 shares of company stock valued at $271,675 in the last ninety days. Corporate insiders own 6.81% of the company’s stock.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AQST. Bratton Capital Management L.P. purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at $40,813,585. BlackRock Inc. purchased a new position in shares of Aquestive Therapeutics during the second quarter worth $33,569,000. Bank of America Corp DE raised its holdings in shares of Aquestive Therapeutics by 99.2% during the first quarter. Bank of America Corp DE now owns 2,405,050 shares of the company’s stock worth $9,981,000 after purchasing an additional 1,197,459 shares during the last quarter. Wasatch Advisors LP raised its holdings in shares of Aquestive Therapeutics by 57.8% during the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock worth $5,765,000 after purchasing an additional 507,527 shares during the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new position in Aquestive Therapeutics during the second quarter valued at $3,923,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.